Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Qiagen N.V. (NY: QGEN )

43.34 +0.09 (+0.21%)
Streaming Delayed Price Updated: 11:55 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V.

< Previous 1 2 3 4 5 6 Next >
The 3 Most Promising Biotech Stocks to Buy Now
With the NIH requesting its biggest budget yet, these are the three most promising healthcare stocks to buy now. 
Via InvestorPlace
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
From QIAGEN N.V.
Via Business Wire
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
From QIAGEN N.V.
Via Business Wire
Will Investors Notice Exciting Sign On Qiagen's Chart?
Via Benzinga
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
From QIAGEN N.V.
Via Business Wire
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
From QIAGEN N.V.
Via Business Wire
Genetic Technologies Shares Jump After Strategic Alliance With Qiagen
Genetic Technologies Limited (NASDAQ: GENE) agreed to form a strategic alliance with Qiagen NV (NYSE: QGEN) to establish and develop a 'Centre of Excellence facility in Australia. 
Via Benzinga
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories
Bloomberg 
Via Benzinga
QIAGEN Acquires Verogen Strengthening Its Position In Human ID / Forensics
Via Benzinga
QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies
From QIAGEN
Via Business Wire
QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases
From QIAGEN N.V.
Via Business Wire
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
From QIAGEN N.V.
Via Business Wire
QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance
From QIAGEN N.V.
Via Business Wire
QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook
From QIAGEN N.V.
Via Business Wire
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million. 
Via Benzinga
A Preview Of Qiagen's Earnings
Qiagen (NYSE:QGEN) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Qiagen will report an... 
Via Benzinga
QIAGEN N.V. to Release Results for Q3 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely
One analyst doubts any deal could come to fruition. If it did, it would make sense. 
Via Investor's Business Daily
Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11
Reuters US-China Chip War: KLA Relaxes Chip Supply To China 
Via Benzinga
Bio-Rad Laboratories, Qiagen Mull Merger Of Equals
Bio-Rad Laboratories Inc (NYSE: BIO) is reportedly in talks to merge with Qiagen NV (NYSE: QGEN), but any agreement isn't likely for another few weeks or more, or it may not happen at all. 
Via Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Via Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
IGI Inex Holding (UK) Becomes Strategic Investor in Quantumrock, Cementing Partnership Between Leading Global Investment Group and AI Asset Tech Frontrunners
Via ACCESSWIRE
QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System
From QIAGEN N.V.
Via Business Wire
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
From QIAGEN N.V.
Via Business Wire
No More Free COVID-19 At-Home Tests, Federal Government Says
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au 
Via Benzinga
QIAGEN Issues 2021 Sustainability Report
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.